Leukemia, Lymphoma, Multiple Myeloma and Plasma Cell Neoplasm, Myelodysplastic Syndromes
Conditions
Keywords
adult acute myeloid leukemia with 11q23 (MLL) abnormalities, recurrent adult acute myeloid leukemia, secondary acute myeloid leukemia, adult acute myeloid leukemia in remission, adult acute erythroid leukemia (M6), adult acute megakaryoblastic leukemia (M7), adult acute monoblastic leukemia (M5a), adult acute monocytic leukemia (M5b), refractory multiple myeloma, adult acute lymphoblastic leukemia in remission, accelerated phase chronic myelogenous leukemia, blastic phase chronic myelogenous leukemia, relapsing chronic myelogenous leukemia, chronic phase chronic myelogenous leukemia, stage II multiple myeloma, stage III multiple myeloma, recurrent adult acute lymphoblastic leukemia, recurrent adult diffuse large cell lymphoma, stage III adult diffuse large cell lymphoma, recurrent mantle cell lymphoma, stage III mantle cell lymphoma, recurrent adult Hodgkin lymphoma, stage III adult Hodgkin lymphoma, adult acute myeloid leukemia with inv(16)(p13;q22), adult acute myeloid leukemia with t(15;17)(q22;q12), adult acute myeloid leukemia with t(16;16)(p13;q22), adult acute myeloid leukemia with t(8;21)(q22;q22), de novo myelodysplastic syndromes, previously treated myelodysplastic syndromes, secondary myelodysplastic syndromes, recurrent adult T-cell leukemia/lymphoma, stage IV adult diffuse large cell lymphoma, stage IV adult Hodgkin lymphoma, stage IV adult T-cell leukemia/lymphoma, stage IV mantle cell lymphoma, stage III adult T-cell leukemia/lymphoma, stage I multiple myeloma
Brief summary
RATIONALE: Giving chemotherapy, such as fludarabine, busulfan, and etoposide, before a donor umbilical cord blood stem cell transplant helps stop the growth of cancer cells. When the healthy stem cells from a donor are infused into the patient they may help the patient's bone marrow make stem cells, red blood cells, white blood cells, and platelets. Sometimes the transplanted cells from a donor can make an immune response against the body's normal cells. Giving antithymocyte globulin before transplant and tacrolimus and prednisone after transplant may stop this from happening. PURPOSE: This phase I trial is studying how well donor umbilical cord blood transplant works in treating patients with advanced hematologic cancer.
Detailed description
OBJECTIVES: Primary * Determine the safety and feasibility of performing donor umbilical cord blood transplantation (UCBT) in patients with advanced hematologic malignancies, in terms of \> 80% engraftment rate at day 100 post-transplant and ≤ 50% transplant-related mortality. Secondary * Determine the toxicity of a myeloablative preparative regimen comprising busulfan, fludarabine, and etoposide prior to UCBT in these patients. * Determine the neutrophil and platelet recovery in patients treated with this regimen. * Determine the event-free and overall survival of patients treated with this regimen. * Evaluate lineage-specific chimerism after UCBT and assess the contribution of each individual cord blood unit to post-transplantation hematopoiesis in these patients. * Determine the incidence, severity, and timing of acute and chronic graft-vs-host disease in patients treated with this regimen. OUTLINE: This is a pilot study. * Preparative regimen: Patients receive fludarabine IV over 30 minutes on days -7 to -3, busulfan IV over 2 hours 4 times daily on days -7 and -4, etoposide IV over 4 hours on day -3, and anti-thymocyte globulin IV over 6 hours on days -2 and -1. * Donor umbilical cord blood transplantation (UCBT): Patients undergo donor UCBT on day 0. Beginning on day 7, patients receive sargramostim (GM-CSF) IV or subcutaneously once daily until blood counts recover. * Graft-vs-host disease prophylaxis: Patients receive tacrolimus IV continuously over 24 hours or orally twice daily beginning on day -2 and continuing until day 180 followed by a taper. Patients also receive oral prednisone twice daily on days 13-50 and then once daily on days 50-60, followed by a rapid taper. After completion of study treatment, patients are followed periodically for approximately 2 years. PROJECTED ACCRUAL: A total of 10 patients will be accrued for this study.
Interventions
BIOLOGICALanti-thymocyte globulin
BIOLOGICALsargramostim
DRUGbusulfan
DRUGetoposide
DRUGfludarabine phosphate
DRUGprednisone
DRUGtacrolimus
PROCEDUREallogeneic hematopoietic stem cell transplantation
PROCEDUREumbilical cord blood transplantation
Sponsors
National Cancer Institute (NCI)
University of California, San Francisco
Study design
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
18 Years to 55 Years
Healthy volunteers
No
Inclusion criteria
DISEASE CHARACTERISTICS: * Diagnosis of 1 of the following advanced hematologic malignancies: * Acute myeloid leukemia (AML) meeting the following criteria: * Not expected to be curable with chemotherapy and meets ≥ 1 of the following criteria: * High-risk cytogenetics (-7, -7q, -5, -5q, t\[6,9\], t\[9,11\], complex, Philadelphia chromosome positive \[Ph+\]) * AML evolved from prior myelodysplasia * AML secondary to prior chemotherapy * Failed to achieve remission * In second or subsequent remission * Marrow blasts ≤ 10% (may be achieved using chemotherapy) * Myelodysplastic syndromes (MDS) with high-risk features * International Prognostic Scoring System (IPSS) score intermediate -2 or high-risk * Marrow blasts ≤ 20% (may be achieved using chemotherapy) * Acute lymphoblastic leukemia meeting the following criteria: * Not expected to be curable with chemotherapy and meets ≥ 1 of the following criteria: * High-risk cytogenetics (Ph+, t\[4,11\], 11q23 abnormalities, and monosomy 7) * Required \> 1 induction course to achieve remission * Failed to achieve remission * In second or subsequent remission * Marrow blasts ≤ 10% (may be achieved using chemotherapy) * Chronic myelogenous leukemia meeting ≥ 1 of the following criteria: * Accelerated phase * Chronic phase refractory to imatinib mesylate * Blastic phase * Marrow blasts ≤ 10% (may be achieved using chemotherapy) * Multiple myeloma meeting 1 of the following criteria: * Stage II or III disease with \> first relapse or refractory disease * Newly diagnosed disease with chromosome 13 abnormalities * Lymphoma meeting the following criteria: * One of the following subtypes: * Diffuse large cell lymphoma * Mantle cell lymphoma * Peripheral T-cell lymphoma * T-natural killer (NK) cell lymphoma * Hodgkin's lymphoma * Disease failed to respond to primary therapy, progressed, or recurred after prior therapy * Patients who have failed autologous stem cell transplantation are eligible provided it has been \> 1 year since transplant * No rapid progression of malignant disease * Not eligible for autologous stem cell transplantation * Available umbilical cord blood (1-3 units) donor matching at ≥ 4 of 6 HLA antigens (A, B, and DR) * Patients with an HLA-identical or 1 antigen-mismatched related donor OR a potential HLA-matched unrelated donor matching at \> 6/8 (A, B, C, DR) alleles are not eligible PATIENT CHARACTERISTICS: * ECOG performance status 0-2 * Creatinine \< 2.0 mg/dL * Creatinine clearance \> 40 mL/min * Bilirubin \< 2.0 mg/dL * AST and alkaline phosphatase \< 3 times upper limit of normal * Hepatitis C and active hepatitis B allowed if patient has ≤ grade 2 inflammation or fibrosis by liver biopsy * Ejection fraction \> 40% by echocardiogram or MUGA * DLCO \> 40% of predicted * Not pregnant or nursing * Negative pregnancy test * No known HIV infection * No active infection requiring ongoing antibiotic treatment PRIOR CONCURRENT THERAPY: * See Disease Characteristics
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Determine the safety and feasibility of performing donor umbilical cord blood transplantation (UCBT) in patients with advanced hematologic malignancies | up to 24 months post-transplant | Determine the safety and feasibility of performing donor umbilical cord blood transplantation (UCBT) in patients with advanced hematologic malignancies, in terms of \> 80% engraftment rate at day 100 post-transplant and ≤ 50% transplant-related mortality. |
Countries
United States
Outcome results
None listed